Inhalation Sciences Sweden AB (ISAB.ST)
- Previous Close
0.6050 - Open
0.5800 - Bid 0.5800 x --
- Ask 0.6250 x --
- Day's Range
0.5800 - 0.6850 - 52 Week Range
0.3440 - 4.0300 - Volume
28,737 - Avg. Volume
194,328 - Market Cap (intraday)
9.48M - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research. The company's products portfolio includes PreciseInhale, a laboratory system that allows scientists to measure how inhaled particles act in lungs and affect the health; DissolvIt, which enables in vitro simulation of dissolution and absorption of respirable particles in the lung epithelium; XposeALI, a 3D cell exposure module that combines aerosol capability with 3D cell models cultured at an air liquid interface; Nose-only inhalation, a standard method of exposure used in preclinical testing of inhalation drugs, as well as for inhalation toxicity studies in rodents; and intratracheal exposure module, an unique technology delivering aerosol directly to the lungs, bypassing the nose, and to spontaneously breathing rodents. Inhalation Sciences Sweden AB (publ) was incorporated in 2004 and is headquartered in Huddinge, Sweden.
www.inhalation.seRecent News: ISAB.ST
View MorePerformance Overview: ISAB.ST
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ISAB.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ISAB.ST
View MoreValuation Measures
Market Cap
9.10M
Enterprise Value
5.10M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.82
Price/Book (mrq)
1.17
Enterprise Value/Revenue
0.46
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-46.59%
Return on Assets (ttm)
-22.11%
Return on Equity (ttm)
-49.58%
Revenue (ttm)
11.05M
Net Income Avi to Common (ttm)
-5.15M
Diluted EPS (ttm)
-0.3400
Balance Sheet and Cash Flow
Total Cash (mrq)
4.45M
Total Debt/Equity (mrq)
5.66%
Levered Free Cash Flow (ttm)
-805.62k